In 2022, the Coordination and Support Action (CSA) DESIGN OH AMR has organised a series of stakeholder and expert consultations to collect input to the update of the research and innovation objectives within the JPIAMR Strategic Research and Innovation Agenda (SRIA). This serves in preparation for the Horizon Europe candidate One Health AMR Partnership.
The reports from the consultations are now available for download.
The JPIAMR has since its launch in 2011 coordinated 13 transnational joint calls till date supporting 99 projects and 38 networks with over 1300 researchers by investing 125 million Euros. In the framework of the CSA DESIGN, JPIAMR is preparing for the future One Health Antimicrobial Resistance (OH AMR) partnership programme including its portfolio for funding instruments. The OH AMR partnership programme will be a research and innovation (R&I) funding programme designed and launched jointly by the European Commission and member states. Using a combination of EU and national public R&I funding, this new programme will contribute to the European One Health Action Plan against AMR and the WHO Global Action Plan on AMR, both aiming to reduce the threat of antimicrobial resistance (AMR).
The aim of this survey is to gather feedback from the AMR research community to understand its views regarding gaps in the AMR funding landscape, and, the requirements for potential funding mechanisms with impact. These funding instruments could be used by JPIAMR member states and the European Commission in the future co-funded programme OH AMR partnership to support R&I and capacity building activities.
Link to survey: https://survey.vr.se/fundinginstrumentsOHAMR
The survey will close on the 26th September 2022 at 12.00 CEST
A report on the outputs, outcome and impact generated by the projects funded in the various JPIAMR transnational research project and network calls under the Therapeutics priority topic has been published.
This report has been prepared using information provided by the coordinators of the research projects and networks in the mid-term and the final term progress reports. The aim is to disseminate information about the outputs and the outcomes of the funded projects and networks to highlight the promising results of the funded research. Some highlights from the report on the main achievements of the Therapeutics research projects and networks and the impact generated are:
Download the report: JPIAMR therapeutics discovery pipeline: Outputs, outcomes and impact of the funded projects and networks in the Therapeutics priority topic of the JPIAMR-SRIA (pdf 0,8 MB)
The development of resistance to antibiotics is a biological process, but the context that determines emergence and impact of resistance is underpinned by social aspects. Therefore, it is necessary to identify, understand and evaluate these social aspects to enable the prevention and control of AMR.
Using the One Health approach means it is vital to include social processes across human and animal health care, in the food production chain and in environmental protection. Questions to ask are, for example: How do farmers, vets, and regulatory systems manage livestock production? How do regulatory and fiscal frameworks incentivise or deter antimicrobial development, production, availability, and use? How do the public and healthcare professionals understand, value, and use antimicrobials?
There is a need for clearer descriptions of how different social scientific fields – economics, political science, ethics, sociology, anthropology, and law – could deepen the understanding of the AMR issue, and also the value from particular methods such as interviews or ethnography. Once the definition, scale, and scope are understood, we can begin to fully understand the potential contribution of perspectives based on the social sciences.
To start introducing social sciences as a cross-cutting theme in the JPIAMR Strategic Research and Innovation Agenda (SRIA) it is necessary to develop a list of key areas to focus on. It will also be necessary to develop quality assessment criteria that are sufficiently broad to capture the range of quantitative and qualitative methods used by social sciences but specific enough to enable a systematic critique. This exercise will also contribute to the development of the candidate Horizon Europe co-fund OH AMR Partnership.
This initiative is led by professor Katherine Payne, University of Manchester, United Kingdom. An expert group has been appointed, consisting of:
The group is currently drafting a working paper that will be sent for wider consultation among experts before being included in the SRIA revision process.
The JPIAMR has launched a round of public consultation on the Strategic Research and Innovation Agenda (SRIA) on Antimicrobial Resistance. The (SRIA) presents an overview of recent developments and future needs for AMR research. More information and the link to the SRIA can be found here: JPIAMR Strategic Research and Innovation Agenda
The updated SRIA outlines five key priority topics within the AMR field: Therapeutics, Diagnostics, Surveillance Transmission and Evolution, and Prevention and Intervention.
The SRIA is a prime guiding tool for AMR research prioritisation in investments, research activities and planning for JPIAMR member states and other funding initiatives. It is also one of the most thorough guidelines on AMR research, helping researchers, policymakers, media, educators, health workers and the scientific community to work together on solutions to curb AMR on a global scale.
You can contribute to the consultation by completing the following survey: JPIAMR SRIA global survey
The survey will be closed on 15th April 2022 at 12.00 CET.
The JPIAMR Activity Report that was published today summarises the JPIAMR achievements and major events for the year 2021.
The transnational project call Disrupting drug resistance using innovative design is now open. The call involves 27 funding organisations from 18 countries and the total estimated call budget is about 19 million Euro.
This call aims to improve the treatment of bacterial and fungal infections (including co-infection) and/or the prevention of the emergence/spread of resistance in humans, animals or plants through the improvement of the efficacy, specificity, delivery, combinations and/or repurposing of drugs and plant protection agents.
The call will follow a two-step evaluation procedure and the deadline for pre-proposals is 8 March 2022.
Read more on the Disrupting drug resistance using innovative design call page.
The outputs, outcomes and the impact generated by the projects supported under the 2016 JPIAMR joint co-funded call “AMR Transmission Dynamics have now been published in a report. The report highlights the effect of supporting excellent science through transnational research collaborations.
Numerous peer-reviewed scientific articles in highly recognised journals have been published by the supported projects on the research findings, and a patent has been filed on a new peptide molecule discovered in one of the projects.
Other impact highlights are:
The third JPIAMR joint co-funded call “AMR Transmission Dynamics” was launched in 2016. The call was conducted by 21 participating funding organisations from 18 countries and was co-funded by the European Commission (EC) within the JPI-EC-AMR ERA-Net co-fund grant . The call resulted in the awarding of 29.1 million euros (M EUR) including a 6.3 M EUR contribution from the EC to 19 research projects. The 19 project consortia included a total of 118 researchers from 16 countries aiming to bridge the knowledge gap on AMR transmission mechanisms.
The call was one of the first of its kind to address transmission of antibiotic resistance following a One Health approach not only focussing the European and North American countries but also including research activities in the low- and middle-income countries (LMIC).
We are pleased to welcome Chile as a new member of JPIAMR. Chile’s participation in JPIAMR is part of the country’s determination to become an active contributor to the world’s efforts to tackle the global challenge of AMR.
Chile is represented in JPIAMR by MICROB-R on behalf of the Ministry of Health.
Tania Herrera, Coordinator Chile National AMR Plan:
-As an JPIAMR member, we expect to advance collaborative efforts on ambitious, innovative, large scale research projects, introducing meaningful progress in our knowledge base to tackle the global challenge of AMR.
Andrea Moreno Switt, Associate Professor, Pontificia Universidad Católica de Chile:
-In the context of Chile’s newly launched version of its AMR National Plan, JPIAMR membership represents our renewed efforts and conviction that Chilean agenda and capabilities on AMR research are having a substantial upgrade, and that we are in solid shape to undertake collaborative projects benefiting the international AMR research community.
Jan-Ingvar Jönsson, JPIAMR Chair:
–On behalf of the JPIAMR Management Board, I am extending a warm welcome to Chile as the 29th member of JPIAMR. It is with great pleasure and excitement that we are including yet another country in Latin America. We are looking forward to create opportunities for researchers in Chile to participate in future calls. The membership will unlock new research collaborations that may contribute to a deeper understanding of AMR and potentially, solutions to one of the key challenges of our time.
Read more on Chile’s national AMR research program and activities.
It is with great pleasure that we acknowledge that JPIAMR officially celebrates ten years as an international collaborative platform. From its inception in December 2011 until today, JPIAMR has achieved and exceeded its mission to coordinate national funding of antimicrobial resistance (AMR) research, guided by a shared strategic research and innovation agenda. Today 28 countries fund AMR research with a One Health approach, as members of JPIAMR. More than 1 400 researchers in 71 countries have been engaged in research that has been funded by JPIAMR members. In total, 125 million Euros have been allocated to research and networking which has achieved outstanding results and impacts. This highlights the role of JPIAMR as a key initiative helping to understand and curb AMR on a global scale.
JPIAMR is leading the development of the One Health AMR Partnership within the Horizon Europe Framework Programme. We look forward to working together with members to seek and support solutions to curb AMR.
“It is impressive to see what JPIAMR members have made possible during these ten years. The results from funded research are astonishing and important, showing that the JPIAMR model works. JPIAMR is well suited to lead the development of the One Health AMR Partnership. We can only imagine what will be achieved in the ten years to come. I am joining all of the members and the AMR research community in wishing JPIAMR a Happy Birthday!” – Jan-Ingvar Jönsson, JPIAMR Chair
See highlights from JPIAMR’s ten year history in the folder “JPIAMR Ten years of achievements” (pdf 0,5 MB)
